Immunovia AB (Immunovia) is a molecular diagnostics company. It offers clinical testing for early diagnosis of pancreatic cancer. The company develops IMMray, a technology platform based on antibody microarray analysis which can be used in the early diagnosis of cancer, predicting disease progression, and monitoring the therapeutic responsiveness of cancers. Immunovia’s IMMray can also be used for biomarker discovery through its discovery tool for proteome scanning. The company also provides IMMray PanCan-d, a blood-based test for the detection of pancreatic cancer. Immunovia is headquartered in Lund, Sweden.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Immunovia AB
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
Immunovia AB Company Overview
Immunovia AB Company Snapshot
Immunovia AB Pipeline Products and Ongoing Clinical Trials Overview
Immunovia AB – Pipeline Analysis Overview
Immunovia AB - Key Facts
Immunovia AB - Major Products and Services
Immunovia AB Pipeline Products by Development Stage
Immunovia AB Ongoing Clinical Trials by Trial Status
Next Generation Pancreatic Cancer Detection Test Product Overview
ProMIS Assay
ProMIS Assay Product Overview
Immunovia AB - Key Competitors
Immunovia AB - Key Employees
Immunovia AB - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Immunovia AB, Recent Developments
Nov 07, 2023: Immunovia successfully completes discovery phase of next-generation test development
Nov 02, 2023: Immunovia Announces Invitation to Q3 Presentation
Aug 30, 2023: Immunovia Publishes Interim Report for January-June 2023
Aug 23, 2023: Immunovia Announces Invitation for Q2 Presentation
Jul 12, 2023: Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer Detection
May 22, 2023: Immunovia: Changes to the nomination committee's proposal to the annual general meeting 2023
Apr 26, 2023: Immunovia to discuss adoption of IMMray PanCan-d with key opinion leaders on May 3, 2023
Apr 21, 2023: Immunovia announces annual report for 2022
Apr 20, 2023: Immunovia to participate in National Pancreas Foundation Webinar on Biomarkers and Liquid Biopsy for early detection of pancreatic cancer
Mar 16, 2023: Immunovia Announces Bulletin from the extraordinary general meeting
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Table 1: Immunovia AB Pipeline Products and Ongoing Clinical Trials Overview
Table 2: Immunovia AB Pipeline Products by Equipment Type
Table 3: Immunovia AB Pipeline Products by Indication
Table 4: Immunovia AB, Key Facts
Table 5: Immunovia AB, Major Products and Services
Table 6: Immunovia AB Number of Pipeline Products by Development Stage
Table 7: Immunovia AB Pipeline Products Summary by Development Stage
Table 8: Immunovia AB Ongoing Clinical Trials by Trial Status
Table 9: Immunovia AB Ongoing Clinical Trials Summary
Table 10: IMMray - Breast Cancer - Product Status
Table 11: IMMray - Breast Cancer - Product Description
Table 12: IMMray - NSCLC - Product Status
Table 13: IMMray - NSCLC - Product Description
Table 14: IMMray - Prostate Cancer - Product Status
Table 15: IMMray - Prostate Cancer - Product Description
Table 16: IMMray PanCan-d - Product Status
Table 17: IMMray PanCan-d - Product Description
Table 18: IMMray PanCan-d - A Prospective Evaluation of IMMray PanCan-d Biomarker Signature Assay in Subjects with New Onset Diabetes (NOD)
Table 19: IMMray PanCan-d - IMMray PanCan-d Utility in Patients with Abdominal Symptoms Attending Secondary Care Centres
Table 20: IMMray PanCan-m Test - Product Status
Table 21: IMMray PanCan-m Test - Product Description
Table 22: IMMray Primary Sjogren’s Syndrome Assay - Product Status